Select country set
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

Procalcitonin Canine ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:PCT
  • Species:Canine
Please select your region to see available products and prices.
Cat. No. Size Price

RD491488200R 96 wells (1 kit)
PubMed Product Details
Technical Data


Sandwich ELISA, Biotin-labelled antibody


Serum, Urine

Sample Requirements

20 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

12.5 – 800 pg/ml

Limit of Detection

3.6 pg/ml

Intra-assay (Within-Run)

n = 8; CV = 4.2 %

Inter-assay (Run-to-Run)

n = 6; CV = 7.1 %

Spiking Recovery

Serum: 95.9 %
Urine: 94.8 %

Dilution Linearity

Serum: 100.1 %
Urine: 94.3 %



  • It is intended for research use only
  • The total assay time is less than 3.5 hours
  • The kit measures canine procalcitonin in serum and urine
  • Assay format is 96 wells
  • Standard is recombinant protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Immune Response, Infection and Inflammation, Sepsis, Animal studies, COVID-19


Procalcitonin (PCT), a polypeptide with a molecular mass of about 13 kDa, is the precursor of calcitonin. PCT is constitutively produced in the C cells of the thyroid gland and does not exhibit hormone activity. It undergoes successive cleavages to form three distinct molecules; calcitonin, katacalcin and an N-terminal fragment called aminoprocalcitonin. PCT belongs to a group of related proteins called the CAPA (CGRP – Amylin – Pro-calcitonin – Adrenomedullin) protein family [3]. Synthesis of PCT is regulated by the CALC-I gene. Circulating levels of PCT in healthy human individuals was found to be very low (depend on source < 0.1 ng/ml or < 0.5 ng/ml).
PCT is rapidly produced and released to peripheral circulation in response to endotoxin and pro-inflammatory cytokines, such as IL-1β and TNF-α. During microbial infection, there is an increase of CALC-I gene expression which causes a release of PCT from all parenchymal tissues and differentiated cell types throughout the body, including the liver and peripheral blood mononuclear cells.
PCT is markedly elevated within 2 to 4 hours in severe forms of systemic inflammation or in bacterial infections, and the level persists until recovery. The biological half-life of PCT is 22 to 26 hours, an advantageous time point compared with CRP and other acute-phase reactants. Because up-regulation of PCT is attenuated by INF-γ, a cytokine released in response to viral infections, PCT is more specific for bacterial infections and may help to distinguish bacterial infections from viral illnesses.
It should be noted that PCT is also elevated in noninfectious conditions such as trauma, surgery, cardiogenic shock, burns, heat stroke, acute respiratory distress syndrome, infected necrosis after acute pancreatitis, and rejection after transplantation.
PCT is used as an early biomarker for the diagnosis of sepsis, severe sepsis and septic shock. PCT has also proved to be useful in guiding antibiotic therapy. This approach was mainly evaluated in patients with respiratory tract infections; however, it can also be used in critically ill patients with sepsis or severe sepsis of various origins.

Severe bacterial infections can result in marked morbidity and death in veterinary patients, with 50–70% of dogs with sepsis succumbing to their disease. Early diagnosis of infection is essential for the appropriate management of sepsis, as it allows rapid administration of antibiotics resulting in improved outcomes. Although PCT mRNA expression from nonthyroidal tissue has been demonstrated in dogs with inflammation, sepsis and SIRS, very little is known about serum PCT concentration in dogs due to the lack of a validated canine assay.

Product References (3)


  • Goggs R, Milloway M, Troia R, Giunti M. Plasma procalcitonin concentrationsare increased in dogs with sepsis. Vet Rec Open. 2018 Apr 12;5(1):e000255. doi:10.1136/vetreco-2017-000255. eCollection 2018. PubMed PMID: 29682292; PubMedCentral PMCID: PMC5905832. See more on PubMed
  • Troia R, Giunti M, Calipa S, Goggs R. Cell-Free DNA, High-Mobility GroupBox-1, and Procalcitonin Concentrations in Dogs With Gastric Dilatation-Volvulus Syndrome. Front Vet Sci. 2018 Apr 9;5:67. doi: 10.3389/fvets.2018.00067.eCollection 2018. PubMed PMID: 29686994; PubMed Central PMCID: PMC5900424. See more on PubMed
  • Troia R, Giunti M, Goggs R. Plasma procalcitonin concentrations predict organ dysfunction and outcome in dogs with sepsis. BMC Vet Res. 2018 Mar 27;14(1):111. doi: 10.1186/s12917-018-1427-y. PubMed PMID: 29580242; PubMed Central PMCID:PMC5870177. See more on PubMed
Summary References (21)

References to Procalcitonin

  • Arkader R, Troster EJ, Lopes MR, Junior RR, Carcillo JA, Leone C, Okay TS. Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome. Arch Dis Child. 2006 Feb;91 (2):117-20
  • Carrol ED, Thomson AP, Hart CA. Procalcitonin as a marker of sepsis. Int J Antimicrob Agents. 2002 Jul;20 (1):1-9
  • Dumea R, Siriopol D, Hogas S, Mititiuc I, Covic A. Procalcitonin: diagnostic value in systemic infections in chronic kidney disease or renal transplant patients. Int Urol Nephrol. 2014 Feb;46 (2):461-8
  • Floras AN, Holowaychuk MK, Hodgins DC, Marr HS, Birkenheuer A, Sharif S, Bersenas AM, Bienzle D. Investigation of a commercial ELISA for the detection of canine procalcitonin. J Vet Intern Med. 2014 Mar-Apr;28 (2):599-602
  • Giunti M, Peli A, Battilani M, Zacchini S, Militerno G, Otto CM. Evaluation of CALC-I gene (CALCA) expression in tissues of dogs with signs of the systemic inflammatory response syndrome. J Vet Emerg Crit Care (San Ant. 2010 Oct;20 (5):523-7
  • Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001 Aug 1;164 (3):396-402
  • Kang YA, Kwon SY, Yoon HI, Lee JH, Lee CT. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. Korean J Intern Med. 2009 Dec;24 (4):337-42
  • Kuzi S, Aroch I, Peleg K, Karnieli O, Klement E, Dank G. Canine procalcitonin messenger RNA expression. J Vet Diagn Invest. 2008 Sep;20 (5):629-33
  • Lee H. Procalcitonin as a biomarker of infectious diseases. Korean J Intern Med. 2013 May;28 (3):285-91
  • Lee JY, Hwang SJ, Shim JW, Jung HL, Park MS, Woo HY, Shim JY. Clinical significance of serum procalcitonin in patients with community-acquired lobar pneumonia. Korean J Lab Med. 2010 Aug;30 (4):406-13
  • Maruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. Physiol Res. 2000;49 Suppl 1:S57-61
  • Meisner M. Update on procalcitonin measurements. Ann Lab Med. 2014 Jul;34 (4):263-73
  • Nanda N, Juthani-Mehta M. Novel biomarkers for the diagnosis of urinary tract infection-a systematic review. Biomark Insights. 2009;4:111-21
  • Pecile P, Miorin E, Romanello C, Falleti E, Valent F, Giacomuzzi F, Tenore A. Procalcitonin: a marker of severity of acute pyelonephritis among children. Pediatrics. 2004 Aug;114 (2):e249-54
  • Pourakbari B, Mamishi S, Zafari J, Khairkhah H, Ashtiani MH, Abedini M, Afsharpaiman S, Rad SS. Evaluation of procalcitonin and neopterin level in serum of patients with acute bacterial infection. Braz J Infect Dis. 2010 May-Jun;14 (3):252-5
  • Sand M, Trullen XV, Bechara FG, Pala XF, Sand D, Landgrafe G, Mann B. A prospective bicenter study investigating the diagnostic value of procalcitonin in patients with acute appendicitis. Eur Surg Res. 2009;43 (3):291-7
  • Schneider HG, Lam QT. Procalcitonin for the clinical laboratory: a review. Pathology. 2007 Aug;39 (4):383-90
  • Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011;9:107
  • Schultz MJ, Determann RM. PCT and sTREM-1: the markers of infection in critically ill patients?. Med Sci Monit. 2008 Dec;14 (12):RA241-7
  • Smolkin V, Koren A, Raz R, Colodner R, Sakran W, Halevy R. Procalcitonin as a marker of acute pyelonephritis in infants and children. Pediatr Nephrol. 2002 Jun;17 (6):409-12
  • Summah H, Qu JM. Biomarkers: a definite plus in pneumonia. Mediators Inflamm. 2009;2009:675753
Related Products Docs